|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.13 USD | +0.63% |
|
+21.77% | +81.86% |
Jan 4 (Reuters) - Inovio Pharmaceuticals Inc has partnered with Advaccine Biopharmaceuticals Suzhou Co Ltd to manufacture and commercialize its COVID-19 vaccine candidate in China, the companies said on Monday.
Under the agreement, Advaccine will have the exclusive right to develop, manufacture and commercialize Inovio's vaccine candidate, INO-4800, in the country. (Reporting by Mrinalika Roy in Bengaluru; Editing by Anil D'Silva)
| 1st Jan change | Capi. | |
|---|---|---|
| +81.86% | 288M | |
| +25.83% | 47.96B | |
| +44.70% | 41.47B | |
| +0.69% | 42.45B | |
| +30.52% | 31.6B | |
| +22.30% | 28.63B | |
| -6.35% | 28.03B | |
| +49.25% | 14.56B | |
| +49.18% | 14.14B | |
| +3.45% | 12.58B |
INOVIO PHARMACEUTICALS, INC. 
